TXG

14.04

3.16% 0.43

Dopo l'orario di chiusura: 14.47 0.43 +3.06%

10 X Genomics Inc (TXG)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.61

Aprire:

$13.52

Volume 24 ore:

1.95M

Relative Volume:

0.97

Capitalizzazione di mercato:

$1.70B

Reddito:

$631.73M

Utile/perdita netta:

$-239.78M

Rapporto P/E:

-7.3508

EPS:

-1.91

Flusso di cassa netto:

$-33.45M

1 W Prestazione:

-1.16%

1M Prestazione:

+5.41%

6M Prestazione:

-29.66%

1 anno Prestazione:

-74.26%

Intervallo 1D:

$13.41

$14.44

Intervallo di 1 settimana:

$13.17

$15.31

Portata 52W:

$12.95

$57.78

10 X Genomics Inc Stock (TXG) Company Profile

Nome

10 X Genomics Inc

Settore

Healthcare (1176)

Industria

Health Information Services (60)

Telefono

(925) 401-7300

Indirizzo

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Dipendente

1,259

Cinguettio

@10xgenomics

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

TXG's Discussions on Twitter

Confronta TXG con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TXG 10 X Genomics Inc	14.04	1.70B	631.73M	-239.78M	-33.45M	-2.02
VEEV Veeva Systems Inc	224.15	36.39B	2.66B	665.91M	1.08B	4.05
SOLV Solventum Corp	66.83	11.55B	8.26B	66.00M	1.17B	0.3682
DOCS Doximity Inc	57.83	10.80B	516.85M	174.11M	217.38M	0.87
HQY Healthequity Inc	94.95	8.23B	1.15B	96.70M	-161.99M	1.09
WAY Waystar Holding Corp	36.82	6.34B	906.14M	-52.62M	89.62M	-0.3621

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-09-03	Iniziato	Leerink Partners	Outperform
2024-07-22	Aggiornamento	Jefferies	Hold → Buy
2024-07-18	Downgrade	JP Morgan	Overweight → Neutral
2024-07-10	Downgrade	Deutsche Bank	Buy → Hold
2024-06-27	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Downgrade	Guggenheim	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Hold
2024-05-01	Downgrade	TD Cowen	Buy → Hold
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-12-12	Aggiornamento	BofA Securities	Underperform → Neutral
2023-07-05	Ripresa	JP Morgan	Overweight
2023-05-10	Iniziato	Barclays	Overweight
2023-03-31	Iniziato	Stephens	Overweight
2023-02-02	Iniziato	UBS	Neutral
2022-12-14	Iniziato	Deutsche Bank	Buy
2022-08-18	Downgrade	Goldman	Neutral → Sell
2022-07-25	Iniziato	Canaccord Genuity	Buy
2022-07-15	Downgrade	BofA Securities	Neutral → Underperform
2022-07-15	Downgrade	William Blair	Outperform → Mkt Perform
2021-10-15	Ripresa	Cowen	Outperform
2021-09-14	Downgrade	BofA Securities	Buy → Neutral
2021-03-15	Iniziato	William Blair	Outperform
2020-12-02	Iniziato	Goldman	Neutral
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-07-10	Iniziato	Stifel	Buy
2020-03-05	Iniziato	Guggenheim	Buy
2020-01-07	Iniziato	Citigroup	Buy
2019-10-07	Iniziato	BofA/Merrill	Buy
2019-10-07	Iniziato	Cowen	Outperform
2019-10-07	Iniziato	JP Morgan	Overweight
2019-09-24	Iniziato	Evercore ISI	Outperform

Mostra tutto

10 X Genomics Inc Borsa (TXG) Ultime notizie

03:31 AM

State Street Corp Has $39.53 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

03:31 AM

Dec 19, 2024

Goldman Sachs Maintains 10x Genomics Inc(TXG) Sell Recommendation - MSN

Dec 19, 2024

Dec 18, 2024

10X Genomics' SWOT analysis: genomics firm navigates challenges, eyes recovery - Investing.com

Dec 18, 2024

Dec 16, 2024

Insider Sellers Might Regret Selling 10x Genomics Shares at a Lower Price Than Current Market Value - Simply Wall St

Dec 16, 2024

Barclays PLC Has $13.61 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 16, 2024

Dec 14, 2024

10X Genomics' SWOT analysis: genomics firm's stock faces instrument demand headwinds - Investing.com

Dec 14, 2024

Dec 11, 2024

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - The Eastern Progress Online

Dec 11, 2024

XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 11, 2024

Dec 10, 2024

10x Genomics Reports Third Quarter 2024 Financial Results - The Eastern Progress Online

Dec 10, 2024

Dec 09, 2024

46,029 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Weiss Asset Management LP - MarketBeat

Dec 09, 2024

Dec 08, 2024

Quantinno Capital Management LP Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 08, 2024

Charles Schwab Investment Management Inc. Has $14.71 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 08, 2024

Dec 07, 2024

10x Genomics (FRA:1KJ) Current Ratio : 4.90 (As of Sep. 2024) - GuruFocus.com

Dec 07, 2024

Dec 06, 2024

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - The Eastern Progress Online

Dec 06, 2024

Point72 Asset Management L.P. Invests $27.78 Million in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 06, 2024

Benjamin Edwards Inc. Buys 57,948 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 06, 2024

10x Genomics (STU:1KJ) Shares Outstanding (EOP) : 121.0 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) Shareholder Yield % : 0.42% (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) EV-to-FCF : 68.14 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (STU:1KJ) Price-to-Operating-Cash-Flow : 50.18 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) 3-Year Revenue Growth Rate : 21.40% (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (MEX:TXG) Shares Outstanding (EOP) : 121 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

Dec 03, 2024

Cinctive Capital Management LP Takes $3.67 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 03, 2024

Dec 02, 2024